Argentina: Need for new test data legislation

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Argentina: Need for new test data legislation

Taking into account the benefits of test data protection, several Latin American countries have integrated proper data protection measures into their national legislation.

During the negotiations over Article 39.3 of the TRIPs Agreement, such long-term benefits to the health of the citizens of all member countries of the World Trade Organization that would result from adequate test data protection enforced by governments were expressly recognised.

As an example of such benefits we can mention that in developed countries (for example, in the United States) the data protection rights and marketing exclusivity granted by the Orphan Drug Act have resulted in a dramatic increase in the number of orphan drugs available to the public.

In the case of developing countries a serious problem is the lack of pharmaceutical products used to treat conditions or diseases that are not normally found in developed countries or when a disease affects only a reduced group of patients in developed countries, but a large number in developing countries. In this situation, the potential markets in developed countries would not always be enough to encourage the spending required for research and testing of such medicines.

Adequate test data protection in both developed and developing countries will create the proper incentives through the creation of a larger market of consumers.

Argentina

Notwithstanding these benefits, Argentina's legislation (Law 24,766 – the Confidentiality Law, Executive Order 150/92) fails to provide effective protection against unfair commercial use or unauthorised disclosure of test and other data generated to obtain marketing approval for pharmaceutical products.

The enactment of new legislation consistent with the TRIPs Agreement would improve the health and standard of living as new and better medications would be available to the general population.

zuccherino.jpg

Daniel R Zuccherino


Obligado & CiaParaguay 610, 17th FloorC1057AAH, Buenos Aires, ArgentinaTel: +54 11 4114 1100Fax: +54 11 4311 5675admin@obligado.com.arwww.obligado.com

more from across site and SHARED ros bottom lb

More from across our site

As the US reflects on 250 years of independence, patent lawyers say innovation is reshaping old hiring priorities, with firms seeking broader IP expertise over specialisation
The Nokia v Acer ruling in the UK suggests arbitration is moving from the sidelines towards the mainstream of global FRAND disputes - and could reshape forum strategy in the process
The Life Sciences Awards is thrilled to present the shortlist for the 2026 Americas Awards
From Türkiye to Poland and Nigeria, firms with deep local roots continue to dominate the top tier, proving that market expertise can outweigh international scale in many CEE, Middle Eastern and African jurisdictions
Former Hoyng Rokh partner Simon Dack takes a leading PMAC role as busy firms continue to jostle for position
Franck Fougere, founder and managing partner of Ananda IP in Thailand, describes how the firm has developed a reputation for patent work and why he believes IP practice is set to change
After two decades at Kass International, Geetha Kandiah discusses the lessons that shaped her career, building an inclusive regional firm, and AI opportunities
Manisha Singh of LexOrbis discusses the need for commercial alignment with clients and why IP lawyers need to have curiosity at their core
As firms expand into integrated IP services, recent hires show the model's appeal – but high-profile departures reveal how quickly questions of depth and durability can emerge
In-house counsel say private practice firms either aren’t conveying sustainability messaging or simply ‘don’t care’, but a mindful approach to the topic could swing pitches
Gift this article